MiMedx Heads Into Earnings With Options Markets Braced for Bad News

MDXG heads into its Q3 2026 print with options markets signalling more defensive positioning than at almost any point in the past year.

The put/call ratio has climbed to 1.64, roughly 1.5 standard deviations above its 20-day average of 1.39 and within touching distance of the 52-week high of 1.74. That level of put demand is notable against a stock that has already fallen 15% over the past month, closing at $3.95 on Wednesday. A modest 6% bounce over the past week has done little to change the bearish tone in the options market. The lending market, by contrast, shows no such urgency. Availability runs at 922%, meaning roughly nine shares are available to borrow for every one already short, the loosest borrow conditions have been in the past year. Short interest of 6.2% of float is meaningful but has fallen about 3% over the past month, moving in the opposite direction from the put positioning. Cost to borrow is just 0.50%, near its lowest level in the period. The borrow market is not telling a squeeze story.

The fundamental debate is about whether the wound-care business can find a floor. Bulls point to the Advanced Surgical segment, which grew 13% year-over-year in Q1 2026, and to management's $40 million restructuring target and a $100 million buyback authorisation. Analysts covering the stock are uniformly constructive in rating, with Craig-Hallum raising its target to $8 from $6 in August and Cantor Fitzgerald holding at $8 with an Overweight. The consensus mean target is $7.40, implying roughly 87% upside from the current price. Bears focus on the damage already done: Medicare reimbursement changes that took effect at the start of 2026 have compressed wound-care pricing, created pre-authorisation friction and forced a roughly 20% cut to annual guidance at the midpoint. The Wound Care segment faces an estimated 50% year-over-year revenue decline in 2026, and about 76% of 2024 revenue came from GPOs and IDNs where pricing pressure is hardest to resist.

One additional backdrop worth noting: ORTEX forecasts an 84% probability that the completion of MiMedx's agreed takeover of Sanara MedTech will trigger a share-count increase in the Russell 2000 and Russell 3000, with an estimated announcement date of 14 December and a trade date around 18 December (dates estimated). That potential mechanical demand from index trackers sits in the background, though the near-term focus is entirely on whether the core wound-care business is stabilising.

The print will test whether management's signal from Q1 that the quarter would mark the trough is proving correct, or whether reimbursement headwinds are proving slower to ease than the buyback-and-restructuring story implies.